|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/445 | (2006.01) |
| A61P 9/00 | (2006.01) | ||
| A61P 25/00 | (2006.01) |
| (11) | Number of the document | 3914247 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20708283.5 |
| Date of filing the European patent application | 2020-01-22 | |
| (97) | Date of publication of the European application | 2021-12-01 |
| (45) | Date of publication and mention of the grant of the patent | 2024-11-13 |
| (46) | Date of publication of the claims translation | 2025-01-27 |
| (86) | Number | PCT/US2020/014531 |
| Date | 2020-01-22 |
| (87) | Number | WO 2020/154354 |
| Date | 2020-07-30 |
| (30) | Number | Date | Country code |
| 201962795524 P | 2019-01-22 | US |
| (72) |
SKUBAN, Nina , US
LAGAST, Hjalmar , US
|
| (73) |
Amicus Therapeutics, Inc. ,
3675 Market Street, Philadelphia, PA 19104,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Migalostato vartojimas mažinant smegenų kraujotakos sutrikimo riziką pacientams, sergantiems Fabri liga |
| USE OF MIGALOSTAT IN REDUCING THE RISK OF CEREBROVASCULAR EVENT IN PATIENTS WITH FABRY DISEASE |
| Payment date | Validity (years) | Amount | |
| 2025-12-18 | 7 | 162.00 EUR |
| 2027-01-22 |